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Case report
In the literature, several cases have been reported of
coronary spasms after the placement of a first-generation
drug-eluting stent; no reports have been published of
spasms in relation to a second-generation drug-eluting
stent designed to decrease neointimal response and more
rapid re-endothelialization [1].
A 55-year-old man was admitted to our hospital with
acute chest pain. He was a smoker and had a history of
hypercholesterolemia. Coronary angiography (CAG)
showed 90% stenosis in the mid-right coronary artery
(RCA) and a moderate occlusion of the left anterior
descendant artery, for which stenting was performed
using a everolimus-eluting (XIENCE PRIME; Abbott
Vascular, California, USA) stentAQ2 (3.5× 28mm; Abbott
Vascular) and then postdilating with a TREK balloon
(4× 8mm) (maximum diameter > 4.25 mm) (Fig. 1). He
was discharged after 1 day of observation. However, the
patient had similar complaints of chest pain 3 days later;
therefore, he was again admitted to our hospital. ECG
showed transient ST elevation of greater than 2 mm in
lead II–III–aVF. We performed CAG withoutAQ3 an exercise
test and without stopping oral vasoactive agents before
CAG because we were concerned about the possibility of
unstable angina because of the presence of resting chest
pain. CAG showed severe vasospasm in the proximal
RCA at the proximal edge of the previously implanted
stent; no other significant lesions were present to account
for the resting chest pain. The spasm was completely
relieved by an intracoronary nitroglycerine injection
during CAG, and also the chest pain and the ECG
changes (Fig. 2). CAG also showed slow flows (TIMI II).
The patient had taken aspirin, ticagrelor, rosuvastatina,
and metoprolol. Because coronary spasm was found, a
calcium channel antagonist (nifedipine 30 mg/day) was
added to antiangina medication after recovery. On follow-
up, the patient has had no recurrence of chest pain at rest.
The rates of angiographic in-stent restenosis, target
lesion, and target vessel revascularization are significantly
lower with drug-eluting stents. However, the specter of
serious, rare idiosyncratic reactions to stents, particularly
drug-eluting stents with polymer and active pharmaco-
logic constituents, remains a concern [2]. To date,
documented vascular compatibility issues include rare
hypersensitivity reactions and persistent abnormal vaso-
motor responses in the drug-eluting stented vessel. If the
drug-eluting stent system is the cause of the spasm, it
could potentially be a reaction to the stainless-steel stent
platform, the polymers, or the medications released [3]. It
is unlikely to be the stainless-steel platform, given the
large number of bare-metal stents used worldwide and
the paucity of similar reports of diffuse spasm.
Endothelial dysfunction may be because of a direct toxic
effect of the released drug, an acute or delayed hyper-
sensitivity reaction (Kounis syndrome) to the drug or the
polymer, or impaired or absent re-endothelialization after
percutaneous coronary intervention barotraumas [4]. In
particular, RCA appears to be affected by the spasm. In
our case, the entire RCA, upstream and downstream of
drug-eluting stent, is spastic. The cause of this particular
sensitivity is not yet clear. Currently, vasospastic angina is
treated with a combination of different classes of calcium
channel blockers and nitrates.
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Fig. 1
First percutaneous coronary intervention. (a) Coronary angiography showed 90% stenosis in the mid-right coronary artery; (b) stenting was performed
using a everolimus-eluting stent (XIENCE PRIME; Abbott Vascular); (c) and then postdilating with a TREK balloon (4×8mm). (d) The procedure was
completed with good results.
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Fig. 2
(a) Right coronary angiogram with coronary spasm of segment 1 is observed before infusion just proximal to the everolimus-eluting stent; (b) right
coronary artery after an intracoronary infusion of isosorbide dinitrate: the coronary spasm has resolved completely.
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